In a recent trial (NCT04542837), the anti-PD-L1/CTLA-4 bispecific antibody KN046, when combined with lenvatinib, was shown to prolong progression-free survival in HCC patients while delaying tumor relapse.432 Future preclinical investigations are recommended to prioritize combination therapies integrating immune checkpoint inhibitors with frontline treatments, with the aim of establishing protocols for eradicating dormant malignancies. The gene discussed is CTLA4; the disease is neoplasm.